BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer

To date, the overall response rate of PD-1 blockade remains unsatisfactory, partially due to limited understanding of tumor immune microenvironment (TIME). B-cell lymphoma 9 (BCL9), a key transcription co-activator of the Wnt pathway, is highly expressed in cancers. By genetic depletion and pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Mei, Wu, Zhongen, Zhou, Yan, Wei, Zhuang, Tian, Enming, Mei, Shenglin, Zhu, Yuanyuan, Liu, Chenglong, He, Fenglian, Li, Huiyu, Xie, Cao, Jin, Joy, Dong, Jibin, Yang, Dehua, Yu, Ker, Qian, Junbin, Lambrechts, Diether, Wang, Ming-Wei, Zhu, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379253/
https://www.ncbi.nlm.nih.gov/pubmed/34417435
http://dx.doi.org/10.1038/s41392-021-00730-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379253/
https://www.ncbi.nlm.nih.gov/pubmed/34417435
http://dx.doi.org/10.1038/s41392-021-00730-0

Ejemplares similares